ComparisonInterventions

Ezetimibe vs PCSK9 Inhibitors

Two add-ons to a statin, very different in power and cost

EzetimibeOral cholesterol-absorption inhibitor

PCSK9 InhibitorsInjectable LDL-lowering therapy

Last reviewed: July 2026
Version: 1.0
Review cadence: Annually

At a Glance

The 30-second view

Additional LDL lowering
Ezetimibe
Modest (~15–20%)
PCSK9 Inhibitors
Very large (~50–60%)
Administration
Ezetimibe
Oral, daily
PCSK9 Inhibitors
Injection, every 2–4 weeks
Cost / access
Ezetimibe
Low (generic)
PCSK9 Inhibitors
High; often gated
Lp(a)
Ezetimibe
Minimal
PCSK9 Inhibitors
Modestly lowers
Typical order
Ezetimibe
Usually tried first
PCSK9 Inhibitors
When more lowering is still needed

Dimension	Ezetimibe	PCSK9 Inhibitors
Additional LDL lowering	Modest (~15–20%)	Very large (~50–60%)
Administration	Oral, daily	Injection, every 2–4 weeks
Cost / access	Low (generic)	High; often gated
Lp(a)	Minimal	Modestly lowers
Typical order	Usually tried first	When more lowering is still needed

Overview

Both are add-ons to statin therapy for people not at their LDL goal, but they differ enormously in potency, delivery, and cost. Ezetimibe is a cheap oral pill with modest effect; PCSK9 inhibitors are potent injectables.

Quick summary

Ezetimibe is usually the first add-on — cheap, oral, well tolerated, with a modest LDL reduction and add-on outcome benefit. PCSK9 inhibitors lower LDL far more (and modestly lower Lp(a)) with proven event reduction, but cost and injection reserve them for higher-risk patients still not at goal after statin ± ezetimibe. They are often sequential, not either/or.

When each is appropriate

Choose Ezetimibe

As the first, inexpensive add-on when a statin alone isn't enough.

Choose PCSK9 Inhibitors

For high-risk patients who need much larger LDL lowering (or Lp(a) reduction) beyond statin ± ezetimibe.

Evidence comparison

LDL reduction (added)
Ezetimibe
~15–20%
PCSK9 Inhibitors
~50–60%
Outcome evidence
Ezetimibe
Add-on benefit (IMPROVE-IT)
PCSK9 Inhibitors
Add-on benefit (FOURIER, ODYSSEY)
Lp(a) effect
Ezetimibe
Minimal
PCSK9 Inhibitors
Modest reduction
Delivery
Ezetimibe
Oral
PCSK9 Inhibitors
Injectable

Dimension	Ezetimibe	PCSK9 Inhibitors
LDL reduction (added)	~15–20%	~50–60%
Outcome evidence	Add-on benefit (IMPROVE-IT)	Add-on benefit (FOURIER, ODYSSEY)
Lp(a) effect	Minimal	Modest reduction
Delivery	Oral	Injectable

Safety comparison

Common issues
Ezetimibe
Very well tolerated
PCSK9 Inhibitors
Injection-site reactions; well tolerated

Dimension	Ezetimibe	PCSK9 Inhibitors
Common issues	Very well tolerated	Injection-site reactions; well tolerated

Cost & accessibility

Cost / access
Ezetimibe
Low (generic)
PCSK9 Inhibitors
High; access often gated

Dimension	Ezetimibe	PCSK9 Inhibitors
Cost / access	Low (generic)	High; access often gated

Strengths & limitations

Ezetimibe

Cheap, oral, well tolerated

Sensible first add-on

Modest effect

PCSK9 Inhibitors

Very large LDL lowering

Lowers Lp(a); proven event reduction

Injectable; high cost and access barriers

Frequently asked questions

Do I choose one or the other?

Usually it's a sequence, not a choice: ezetimibe is the inexpensive first add-on to a statin, and a PCSK9 inhibitor is added when much more LDL lowering is still needed in a high-risk person.

Continue Exploring

Where to go next

References & sources

IMPROVE-IT
FOURIER
ODYSSEY OUTCOMES
2018 ACC/AHA Cholesterol Guideline

Comparisons synthesize BioSignal's existing calibrated evidence — they introduce no new conclusions. Figures and verdicts trace to the linked Signal Records and Foundations.

Educational information — not medical advice

Comparisons orient a decision; they don't make it for you. Choices between medications, supplements, or programs belong with a qualified clinician. See our Medical Disclaimer.

Is this comparison clear, balanced, and useful? Your feedback shapes what we review next.

Give feedback